In 2011, the FDA approved a drug that many hoped would be the first step forward in blood thinning medication since Coumadin’s debut in the 1960s: Xarelto.
Created by Johnson & Johnson and Bayer, Xarelto has been responsible for over $3.2 billion in profits for its manufacturers and developers. It has also become Bayer’s top-selling medication ever. Yet despite its successes on paper, the reality is that more than 18,000 ...
continue reading...